What question did this study set out to answer?

This trial investigates the effectiveness and safety of abatacept in rheumatoid arthritis patients unresponsive to TNF-alpha inhibitors.

September 14, 2005New England Journal of MedicineOpen Access

Abatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor α Inhibition

View Full Paper

Ask AI

Bookmark

Authors

MGMark C. GenoveseEli Lilly (United States)JBJean‐Claude BeckerPfizer (United States)MSMichael SchiffUniversity of Colorado Denver

Discussion

Member takes

Implication

Randomized trial demonstrates efficacy of abatacept improving clinical outcomes in rheumatoid arthritis patients, suggesting a viable alternative to TNF-alpha inhibitors.

Key Points

This trial investigates the effectiveness and safety of abatacept in rheumatoid arthritis patients unresponsive to TNF-alpha inhibitors.
Conducted as a randomized, double-blind, phase 3 trial
Patients received either abatacept or placebo alongside disease-modifying antirheumatic drugs
Efficacy assessed through ACR responses and HAQ disability index scores over six months.
ACR 20 response rates were 50.4% for abatacept vs. 19.5% for placebo (P<0.001)
Significant improvement in HAQ disability index scores (47.3% vs. 23.3% for placebo, P<0.001)
Serious infection rates were 2.3% in both treatment groups.

Cite This Study

Genovese et al. (2005) studied this question.

synapsesocial.com/papers/6a24c4fe390a1827e4d3fcdb https://doi.org/10.1056/nejmoa050524

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial demonstrates efficacy of abatacept improving clinical outcomes in rheumatoid arthritis patients, suggesting a viable alternative to TNF-alpha inhibitors.

Abatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor α Inhibition

Discussion

Member takes

Implication

Key Points

Cite This Study

Abatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor α Inhibition

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider